BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s): BVAXF

Healthcare Biotechnology

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp.

Bullboard Posts

Post by seanmac12on May 19, 2020 2:13pm

63 Views

Post# 31047168

Price by depth

Bid Count	Bid Size	Bid Price	Ask Price	Ask Size	Ask Count
1	3,000	0.375	0.39	16,000	3
1	500	0.37	0.4	15,000	3
1	10,000	0.365	0.405	5,000	1
2	17,000	0.36	0.42	5,000	1
2	45,000	0.355	0.45	2,000	1